CEL-SCI Corp (CVM)
0.29
0.00 (0.00%)
USD |
NYAM |
Apr 30, 16:00
0.29
0.00 (0.00%)
After-Hours: 17:59
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 22.39M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -79.43% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 1.98 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.17% |
Profile
Edit
| CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia. |
| URL | https://www.cel-sci.com |
| Investor Relations URL | https://cel-sci.com/new-investor-information/ |
| HQ State/Province | Virginia |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | May. 15, 2025 (est.) |
| Last Earnings Release | Feb. 13, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Aug. 28, 1996 |
Ratings
Profile
Edit
| CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia. |
| URL | https://www.cel-sci.com |
| Investor Relations URL | https://cel-sci.com/new-investor-information/ |
| HQ State/Province | Virginia |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | May. 15, 2025 (est.) |
| Last Earnings Release | Feb. 13, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Aug. 28, 1996 |